Thunder Biotech is developing MOTO-CAR immunotherapy, which genetically engineers macrophages to target and eliminate solid tumors by enhancing the immune system's ability to recognize cancer cells. This approach addresses the limitations of traditional cancer treatments by providing a more effective and less invasive option for patients.
Funding
$65.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments like surgery, radiation, and chemotherapy can be invasive and difficult for patients to tolerate, often failing to fully eliminate solid tumors and leading to recurrence. The body's immune system often fails to recognize and eliminate mutated cells, allowing them to proliferate and form tumors.
Solution
Thunder Biotech is developing MOTO-CAR immunotherapy, a novel approach that genetically engineers a patient's own macrophages to target and destroy solid tumors. This therapy modifies macrophages into MOTO-CAR, which are designed to recognize specific biomarkers on the surface of tumor cells. Once identified, these MOTO-CAR activate the patient’s immune system to attack and eliminate the cancer cells, offering a more compassionate and effective treatment option. By leveraging the natural power of macrophages, Thunder Biotech aims to provide long-term, anti-tumor immunity and improve patient outcomes.
Target Audience
The primary target audience includes cancer patients with solid tumors who are seeking more effective and less invasive treatment options, as well as oncologists and medical professionals specializing in cancer immunotherapy.
Features
- Genetically engineered macrophages (MOTO-CAR) that target specific biomarkers on tumor cells.
- Activation of the patient's own immune system to destroy cancer cells.
- Potential for long-term, anti-tumor immunity.
- Innovative macrophage technology designed to provide a more effective and humane treatment for patients with solid tumors.